Genentech, Inc.

Foundation Medicine, Inc.

Christiaan Nicolaas Klijn

James M Lee

David Hugh Stokoe

Robert Gentleman

Florian Gnad

Leonard David Goldstein

Juliann Chmielecki

Ryan J Hartmaier

Shiva Malek

Ivana Yen

James Lee

The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

Diagnostic and therapeutic methods for cancer

The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.

Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene

Growing community of inventors

San Francisco, CA, United States of America

Christiaan Nicolaas Klijn